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Abstract
Background: The lung disease of cystic fibrosis is associated with a chronic inflammatory reaction and an over abundance of
oxidants relative to antioxidants. Glutathione functions as a major frontline defense against the build-up of oxidants in the lung.
This increased demand for glutathione (GSH) in cystic fibrosis may be limiting if nutritional status is compromised. We sought
to increase glutathione levels in stable patients with cystic fibrosis by supplementation with a whey-based protein. Methods:
Twenty-one patients who were in stable condition were randomly assigned to take a whey protein isolate (Immunocal, 10 g twice
a day) or casein placebo for 3 months. Peripheral lymphocyte GSH was used as a marker of lung GSH. Values were compared
with nutritional status and lung parameters. Results: At baseline there were no significant differences in age, height, weight,
percent ideal body weight or percent body fat. Lymphocyte GSH was similar in the two groups. After supplementation, we
observed a 46.6% increase from baseline (P-0.05) in the lymphocyte GSH levels in the supplemented group. No other changes
were observed. Conclusion: The results show that dietary supplementation with a whey-based product can increase glutathione
levels in cystic fibrosis. This nutritional approach may be useful in maintaining optimal levels of GSH and counteract the
deleterious effects of oxidative stress in the lung in cystic fibrosis.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The lung disease of cystic fibrosis (CF) is character-
ized by a chronic inflammatory reaction. Central to this
response is an intense neutrophil recruitment with a
release of inflammatory cytokines resulting in an over-
abundance of oxidants relative to anti-oxidants. It is
believed that patients with the mutant CFTR have
increased pro-inflammatory cytokines. While the exact
mechanism for this has not been elucidated prolonged
Nuclear Factor kappa-B (NFkB) activation has been
implicated w1x. Treatments that block this activation
could be useful in the management of cystic fibrosis.
Reactive oxygen species stimulate NFkB activation and
increasing the levels of anti-oxidants such as glutathione
(GSH) may counteract this w2,3x. In the lung, glutathione
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functions as a major front-line defense against oxidants.
In a recent study w4x we showed that peripheral circu-
lating lymphocyte glutathione concentration increases
proportionately with nutritional status and at the same
time inversely with lung function. The increasing
demand for glutathione in the face of ongoing inflam-
mation suggests that precursors of glutathione synthesis
may be limiting if nutritional status is compromised. In
this study we sought to increase lung glutathione levels
in stable patients with cystic fibrosis by supplementation
with a whey-based protein. We have previously shown
in healthy young adults that supplementation with a
whey-based protein increased lymphocyte glutathione
levels w5x. Studies in rodents demonstrate that lympho-
cyte glutathione levels reflect lung levels w6,7x. There
was no change in the lymphocyte glutathione in subjects
given a casein-based diet. The whey-based supplement
is richer in cysteine an important precursor of glutathi-
one. Our results show a significant increase in lympho-
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cyte glutathione levels in patients with cystic fibrosis
after supplementation.
2. Materials and methods
Twenty-four patients (12M, 12F) were enrolled (13
whey, 11 casein placebo) and twenty-one (9M, 12F)
completed the trial (10 whey, 11 placebo). The diagnosis
of CF was based upon a positive sweat chloride test
()60 mmolyl) and a compatible history. The patients
were stable, i.e. not admitted nor had a course of oral
corticosteroids within the previous 2 months. They had
mild to moderate lung disease (FEV )40% predicted),1
and were not severely malnourished (weight )75%
ideal). CF patients were recruited from the two adult
CF centres in Montreal (Montreal Chest Institute &
Hopital Hotel Dieu). After signing informed consents,ˆ
subjects were randomly assigned to take either a whey
protein isolate (Immunocal, 10 gydose twice daily) or
an equivalent amount of casein placebo for 3 months.
Randomization was done with alternating block-of-four
and block-of-two design, using numbers from a com-
puter-generated random number table. Both Immuno-
cal and casein placebo were provided by Immunotec
Research, Vaudreuil, Quebec. Subjects were supplied
with a canister containing a 30-day supply. Both whey
and casein were provided as a fine white powder with
no discernable differences in colour, taste, or texture.
Subjects returned each month for a refill of their treat-
ment. The change in weight of the canister was used as
an indicator of compliance. Both subjects and principal
investigators were blinded as to which supplement was
given until the subject completed the trial.
Subjects were studied in the morning, 3–4 h after a
standardized breakfast (1 glass of low-fat milk, 2 slices
of unbuttered toast with jam, and 1 glass of juice).
Subjects underwent the same measures at the beginning
and end of the trial.
Subjects in stocking feet had their height measured
on a stadiometer, and their weight was recorded while
they were lightly clothed and standing on an electronic
balance. Weight was also expressed as a percentage of
ideal weight for height and age w8x. Triceps and sub-
scapular skinfold thickness were used to assess their
percentage of body fat w9x. Expiratory spirometry was
performed according to ATS standards, and results
reported as percent of predicted values w10,11x.
Subjects had 10 ml of blood drawn from an antecu-
bital vein into a heparinized syringe for analysis of
lymphocyte GSH concentration on two different days in
the same week before and after the study. The mean of
the two measurements was used for pre- and post-
supplementation comparison.
2.1. Lymphocyte preparation
Blood was diluted in an equal amount of RPMI-1640
medium, and the resultant mixture was placed in a tube
containing 4 ml of Ficoll-Hypaque and centrifuged at
400 g (1400 rpm, IEC-7) for 30 min. The cells at the
interface (90% lymphocytes) were removed by pipette
and resuspended in 10 ml of 4 8C RPMI-1640 and kept
on ice. The suspension was then centrifuged at 450 g
(1800 rpm) in a 4 8C centrifuge (IEC-PR6) for 10 min.
After removal of the supernatant, the pellet was washed
again in cold RPMI-1640. The pellet was resuspended
in 4 ml of 1=PBS (pH 7.40), and a 0.2-ml aliquot was
removed for automated cell counting (Coulter S-plus
JR). The cell count was used to calculate the suspension
volume required for a 2=10 lymphocyte aliquot.6
Aliquots of appropriate volume were then centrifuged
in prechilled tubes at 500 g (800 rpm, Eppendorf 5402)
for 10 min at 4 8C. The supernatant was removed, and
the pellet was resuspended in 970 ml of cold, distilled
water. To this, 30 ml of 30% 5-sulfosalicylic acid (SSA),
were added to make a final concentration of 0.9% SSA,
and the solution was incubated for 15 min on ice. The
solution was then centrifuged at 5000=g (8000 rpm,
Eppendorf 5402) for 10 min at 4 8C. The supernatant
was removed and stored at y70 8C for later analysis of
GSH.
2.2. GSH analysis
Total GSH in the 0.9% SSA extract was determined
by the glutathione reductase recycling method of Tietze
w12x and adapted for the Cobas Mira spectrophotometer
(Roche Diagnostics) w13x. Briefly, the Cobas Mira
pipettes 210 ml NADPH (0.3 mmolyl), 30 ml 5,59
dithiobis-2-nitrobenzoic acid (DTNB) (6.0 mmolyl),
and 95 ml of sample, standard, or 0.9% SSA into
cuvettes. After a 4-min incubation at 37 8C, 15 ml
glutathione reductase (1.0 Uy100 ml) are added, and
the reaction is monitored every 24 s for 12 min. Under
these conditions, the method is linear for GSH concen-
trations between 0 and 6 mmolyl. The instrument con-
structs a calibration curve by assaying known GSH
standards, and from this the GSH concentration of the
unknown is evaluated. Reproducibility for GSH at these
concentrations is -2% (intra-assay coefficient of vari-
ation). Laboratory control mean value (ns9) is 1.55
nmoly10 lymphocytes, with a range of 1.17–2.176
nmoly10 lymphocytes.6
2.3. Data analysis
Statistical analysis was performed by using Statistica
5.1 for Windows (Statsoft, Tulsa, OK). Data were
expressed as means "S.D. The groups’ baseline data
were compared by unpaired t-testing. Changes from
baseline within each group were assessed by paired t-
testing, and the changes between the groups by unpaired
t-testing. The study was powered (80%) to detect a 30%
increase in lymphocyte GSH levels in the whey-supple-
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Table 1
Baseline characteristics of patients
Supplemented Placebo
Age (years) 25.5"6.35 24.27"3.95
Height (cm) 165"9.04 168"8.24
% Body fat (%) 17.7"6.03 17.3"7.23
% IBW (%) 91.3"12.85 86.6"9.45
Weight (kg) 57.3"11.77 58.2"7.72
FEV (% predicted)1 65.9"19.41 70.5"21.17
Lymphocyte GSH (nmoly10 cells)6 1.62"0.32 1.91"0.47
Values are means "S.D.; supplemented and placebo groups were
administered Immunocal 20 gyday or casein, respectively.
Table 2
Percent change from baseline
Supplemented Placebo
% Body fat 5.34"7.07 1.4"7.23
Weight 0.03"3.2 0.2"2.84
FEV1 y7.0"9.23 4.0"15.33
Lymphocyte GSH 46.6"55.1* 5.0"28.9
Significantly different from baseline, P-0.05.*
mented group. A P value -0.05 was considered as
significant.
3. Results
Results for the 21 patients (10 whey, 11 placebo)
completing the trial are reported. The three whey patients
were dropped from the analysis because of loss to
follow-up (1), non-compliance (1), and infection and
pneumothorax requiring in-hospital intravenous antibi-
otics (1). At baseline there were no significant differ-
ences in age, height, weight, percent ideal body weight,
or percent body fat (Table 1). Lymphocyte GSH levels
was also similar in the two groups. Mean values for
GSH at baseline for the two baseline days were
1.60"0.29 and 1.63"0.38 (average 1.62"0.32) nmoly
10 cells for the whey group, and 1.82"0.46 and6
2.00"0.65 (average 1.91"0.47) nmoly10 cells for the6
casein group. The results in Table 2 show a significant
increase (46.6%) in the lymphocyte GSH levels
(2.14"0.37 and 2.32"0.88, average 2.23"0.55 nmoly
10 cells). No such changes were seen with the placebo6
group (2.02"0.90 and 1.92"0.83, average 1.97"0.61
nmoly10 cells). There was no significant change in6
%body fat, weight or lung function in either of the
groups
4. Discussion
We have demonstrated that ingestion of a native whey
supplement at a dose of 10 g twice daily resulted in a
46.6% increase in circulating lymphocyte GSH concen-
tration. Lymphocyte GSH was used as a marker of tissue
GSH as evidence from animal studies suggested that
this could track tissue levels in response to both L-2-
oxothiazolidine-4-carboxylic acid, a cysteine precursor
w6x, and buthionine sulfoxamine, an inhibitor of the first,
rate-limiting step in GSH synthesis, g-glutamylcysteine
synthase w7x.
The lung inflammation of cystic fibrosis is associated
with an increased oxidative stress and this places
demands on the use of GSH. In a previous study w4x we
demonstrated that lymphocyte GSH levels varied
inversely with lung function and proportionately with
nutritional status. This suggested that in response to
oxidative stress the respiratory epithelium upregulates
GSH production, both de novo synthesis and recycling,
with a resultant increase in intracellular levels of GSH.
The de novo synthesis of GSH demands an increased
supply of precursors, most notably cysteine, which is
considered to be rate limiting w14x. When nutritional
status is compromised, less cysteine may be available
for GSH synthesis. Here we demonstrate that GSH
levels can be increased with the supplementation of a
cysteine rich whey protein.
Patients with cystic fibrosis have decreased levels of
glutathione in the extracellular lining fluid. CFTR has
recently been implicated in GSH efflux w15x. Cells
containing defective CFTR secrete less GSH than cells
with wild-type CFTR. Although the CFTR defect results
in lower efflux of glutathione, the extracellular lining
fluid (ELF) of CF patients does contain glutathione
suggesting that this may not be the only mechanism of
export w16x. Glutathione can also be metabolized in the
ELF by increased g-glutamyl transpeptidase activity
w17x. While inhibition of g-glutamyl transpeptidase
increased the GSH in the apical fluid, it did not
completely restore the levels to that of the cells trans-
fected with CFTR w16x. Although we did not measure
glutathione in the sputum, increased level of lung tissue
glutathione in the CF patients after whey supplementa-
tion may serve to increase the ELF levels.
Recently, Velsor et al. w18x have shown that both
uninfected CFTR-KO mutant and wild-type mice had
similar levels of glutathione in lung tissue but that the
CFTR mutant had lower glutathione levels in ELF fluid.
Unlike CF patients these animals lack spontaneous lung
inflammation. Nonetheless there was increased tissue
lipid oxidation and oxidation of DNA bases in the lung
tissue of the CFTR-KO mice implying that the CFTR
gene defect contributes to the oxidative stress w18x. This
is reminiscent of the clinical situation wherein there is
evidence that the CF lung epithelium may be pro-
inflammatory w19x.
In this study we did not observe any difference in
effect on lung function in the two groups of patients.
This suggests that the increased lung tissue GSH levels
did not reverse the effects. Most likely it arrests the
further damage but a study of longer duration is needed
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to assess this. These results are similar to the experience
with high-dose ibuprofen w20x whereby adults with well
established disease did not see any changes in lung
function, while children had a dramatic slowing of their
disease progression. Preliminary work in a murine model
suggests that use of whey prior to significant lung injury
may be particularly beneficial.
The study was limited by the sample size, which was
chosen to demonstrate a 30% increase in lymphocyte
GSH in the whey-supplemented group. This sample size
did not allow us to look at other factors that could
change with glutathione augmentation, such as inflam-
matory markers and body composition. However, it was
important to show that, like healthy young adults, adult
patients with CF can have their glutathione stores
increased, using nutritional supplementation. We still
need to examine how such increases in glutathione
would be beneficial in CF. With the use of cell lines,
we are now examining the effect of novel whey proteins
on downregulating the inflammatory response in lung
epithelia with either wild-type or mutant CFTR. We will
also continue our work with a murine model of CF lung
disease.
In conclusion, we have shown that dietary supple-
mentation with a whey-based product can increase lym-
phocyte glutathione levels in patients with cystic
fibrosis. Since augmenting GSH levels by systemic
administration of GSH is limited because of rapid
clearance and short plasma half-life w21,22x this nutri-
tional approach can be useful in maintaining optimal
levels of GSH in these patients and potentially counter-
act the deleterious effects of oxidative stress in cystic
fibrosis.
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